Sangamo Therapeutics (SGMO) Misses Q4 EPS by 10c
Tweet
Share
E-mailGet Alerts SGMO Hot Sheet
Price: $0.18 --0%
EPS Growth %: +25.0%
Financial Fact:
Collaboration agreements: 2.73M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +25.0%
Financial Fact:
Collaboration agreements: 2.73M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Sangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of ($0.11), $0.10 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $14.23 million versus the consensus estimate of $33.18 million.
For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
- Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
- HSBC Downgrades Hermes International (RMS:FP) (HESAY) to Hold
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
